Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China

Hui, D. S., I Azhar, E., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C., et al. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.01.009 · Cited by 3,809

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Chan, J. F., Kok, K., Zhu, Z., Chu, H., To, K. K., Yuan, S., & Yuen, K. (2020) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1719902 · Cited by 3,127

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Chen, Y. Z., Liu, Q., & Guo, D. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25681 · Cited by 3,069

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Wu, A., Peng, Y., Huang, B., Ding, X. L., Wang, X., Niu, P., Meng, J., Zhu, Z., Zhang, Z., Wang, J., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.02.001 · Cited by 2,386

The spike protein of SARS-CoV — a target for vaccine and therapeutic development

Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678

The Novel Coronavirus Originating in Wuhan, China

Phelan, A., Katz, R., & Gostin, L. O. (2020) · JAMA · doi:10.1001/jama.2020.1097 · Cited by 1,210

Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines

Whitt, M. A. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.08.006 · Cited by 431

Two cross-neutralizing antibodies isolated from a COVID-19 convalescent via single B cell sorting

Hu, Y.-Y., Hu, C.-Q., Su, J.-W., Zhu, B., Liang, H., & Shao, Y.-M. (2025) · Archives of Virology · doi:10.1007/s00705-025-06372-9

Experimental and computational approaches to adaptive viral evolution: Linking molecular variation to phenotypic outcomes

Huang, Y., Ou, Z., Xue, X., Zhou, H., & Xiao, K. (2025) · Journal of Microbiological Methods · doi:10.1016/j.mimet.2025.107379 · Cited by 1

Mapping immune imprinting zones enables predictive vaccination optimization

Yang, W., Jin, K., Li, W., Ding, Z., Yu, H., Zhou, Z., Su, W., Zhu, X. L., Ma, X., Wan, N., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117271 · Cited by 1

Surrogate virus neutralization test as a scalable and reliable tool for immune surveillance in booster-vaccinated populations

Cai, L., Fang, Z., Zha, R., Zhou, Z., Zhang, R., Li, X., Guo, C., & Liao, C. (2026) · Scientific Reports · doi:10.1038/s41598-026-49973-3 · Cited by 1

An easy method for developing fusion enabled SARS-CoV2 virus fusion mimic (SCFM), bypassing the need of Bio Safety Level (BSL) facility

Das, A., Dutta, S., Sharma, D., Pal, A., Ganguli, N., & Majumdar, S. S. (2021) · Bioengineered · doi:10.1080/21655979.2021.1955509 · Cited by 1

Characterization and use in neutralization assays of avian influenza codon-optimized H5 and H7 retroviral pseudotypes

Delgadillo-Gutiérrez, K., Castelán-Vega, J. A., Jiménez-Alberto, A., Fernández-Lizárraga, M., Aparicio‐Ozores, G., Monterrubio-López, G. P., & Ribas‐Aparicio, R. M. (2021) · Journal of Virological Methods · doi:10.1016/j.jviromet.2021.114391 · Cited by 1

High-affinity aptamers enable the rapid optical detection and differentiation of three SARS-CoV-2 VOCs

Feng, S., Yu, Y., Ma, J., Wang, X., Song, X., Xu, H., Li, Y., Mo, K., Liu, P., Song, X., et al. (2023) · Microchemical Journal · doi:10.1016/j.microc.2023.109508 · Cited by 1

Monovalent Omicron COVID-19 vaccine triggers superior neutralizing antibody responses against Omicron subvariants than Delta and Omicron bivalent vaccine

Li, W., Zhao, T., Tao, B., Zhao, L., Xiao, H., Ding, X., Li, C., Chen, L., Cheng, H. D., Lou, Y., et al. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2264589 · Cited by 1

Packaging systems for generating SARS-CoV-2 pseudoviruses: A mini review

Chin, J. W. T., Budiman, C., & Teoh, P. L. (2023) · Malaysian Journal of Microbiology · doi:10.21161/mjm.230026 · Cited by 1

High-Content Imaging-Based Assay for SARS-CoV-2-Neutralizing Antibodies

Rocha, V. P. C., Machado, B. A. S., Quadros, H. C., Fernandes, A. M. S., Fiuza, B. S. D., Meira, C. S., da Silva, V. T. B., Evangelista, A. F., Fonseca, L. M. D. S., Badaró, R. J. D. S., et al. (2024) · Vaccines · doi:10.3390/vaccines12030236 · Cited by 1

Development of pseudotyped VSV-SARS-CoV-2 spike variants for the assessment of neutralizing antibodies

Çimen, A. N., Torabfam, G. Ç., Tok, Y., Yücebağ, E., Arslan, N., Sarıbal, D., Güney-Esken, G., Doğan, Ö., Kuşkucu, M. A., Mete, B., et al. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2411920 · Cited by 1

Investigating SARS-CoV-2 Neutralising Antibody Response in Sheep

Samojlović, M., Mesquita, J. R., Santos-Silva, S., Neptin, M., & Esbjörnsson, J. (2024) · Microorganisms · doi:10.3390/microorganisms13010049 · Cited by 1

A Live-Cell Imaging-Based Fluorescent SARS-CoV-2 Neutralization Assay by Antibody-Mediated Blockage of Receptor Binding Domain-ACE2 Interaction

Arias-Arias, J. L., Monturiol‐Gross, L., & Corrales‐Aguilar, E. (2025) · BioTech · doi:10.3390/biotech14010010 · Cited by 1

Early transcriptional divergence in mRNA vaccines reveals molecular correlates of humoral efficacy

Wang, Q., Song, Z., Zhang, J., Song, L., Liu, D., Xing, W., Gao, F., Liu, M., Li, L., Wang, Y., et al. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152199 · Cited by 1

Rabies vaccine response in companion animals: Comparative evaluation of VSV-based pseudovirion neutralization test (PVNT) and rapid fluorescent focus inhibition test (RFFIT)

Das, L. J., Lupitha, S. S., Varghese, G. R., Nair, S. R., Lakshman, D., Sharada, R., Isloor, S., & Sreekumar, E. (2025) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2025.111026 · Cited by 1

Rapid Neutralizing Antibody Assessment Using Influenza Viruses with Luciferase Reporter

Pulkina, A., Romanovskaya-Romanko, E., Mustafaeva, A., Egorov, A., & Stukova, M. (2021) · Biotekhnologiya · doi:10.21519/0234-2758-2021-37-2-81-91 · Cited by 1

Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020

Bubba, L., Peter Simmonds, K., Fischer, T. K., Harvala, H., Weseslindtner, L., Spuchhammer-Stockl, E., Marijke, R., Dedeić-Ljubović, A., Aleksandrova, D., Tabain, I., et al. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05014 · Cited by 1

Anti-viral memory T cell responses in the absence of IgG production in a COVID-19 convalescent individual

Ni, L., Ye, F., Qiao, Q., Yu, F., Yang, Y., Zhao, H. J., Zhang, L.-N., Cheng, M., Zhu, G., Li, X., et al. (2022) · National Science Open · doi:10.1051/nso/2021003 · Cited by 1

Optimised Method for the Production and Titration of Lentiviral Vectors Pseudotyped with the SARS-CoV-2 Spike

Mekkaoui, L., Bentley, E. M., Ferrari, M., Lamb, K., Ward, K., Karattil, R., Akbar, Z., Bughda, R., Sillibourne, J., Onuoha, S. C., et al. (2021) · BIO-PROTOCOL · doi:10.21769/bioprotoc.4034 · Cited by 1

Landscape Determinants of Infectivity and Insights into Vaccine Development and Effectiveness - Novel Coronavirus

Hasan, S., Dwivedi, M., Mukhopadhyay, S., & Gupta, N. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180819666220628105636 · Cited by 1

Pre-existing cutaneous conditions could increase the risk for SARS-COV-2 infection.Preprint

Xu, Q. ‐., Chen, L., Zhang, L., Hu, M., Wang, X., Yang, Q., Le, Y., Xue, F., Li, X., & Zheng, J. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.30.181297 · Cited by 1

Co-evolution of COVID-19 Research and China’s PoliciesPreprint

Cheng, X., Tang, L., Zhou, M., & Wang, G. (2020) · Research Square · doi:10.21203/rs.3.rs-69819/v1 · Cited by 1

Editor's evaluation: Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China

Sigal, A. (2023) · eLife · doi:10.7554/elife.84056.sa0 · Cited by 1

COVID‐19

Kulkarni, P., Barot, T. D., Rao, P. K., Dey, A., & Rawtani, D. (2023) · Wiley eBooks · doi:10.1002/9781119777403.ch1 · Cited by 1

How Environmental, Social and Governance (ESG) trends drive sustainable development

Marotta, A. (2023) · doi:10.20868/upm.thesis.78311 · Cited by 1

Emerging SARS-CoV-2 variant BA.3.2 is more poorly neutralized by responses focused on other contemporary strainsPreprint

Stuart, D. I., Dijokaite-Guraliuc, A., Duyvesteyn, H. M. E., Liu, C., Lu, Z.-P., Supasa, P., Kronsteiner, B., Jeffery, K. J., Stafford, L., Klenerman, P., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-9585124/v1 · Cited by 1

COVID-19 için tanısal yaklaşımlar

Karayel-Hacıoğlu, İ. (2020) · Eurasian journal of veterinary sciences · doi:10.15312/eurasianjvetsci.2020.292

Lentiviral vector-based SARS-CoV-2 pseudovirus enables analysis of neutralizing activity in COVID-19 convalescent plasmaPreprint

Pamukcu, C., Çelik, E., Ergun, E. Z., Karahan, Z. S., Turkoz, G., Aras, M., Eren, C., Sili, U., Bilgin, H., Süder, İ., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.28.424590

COVID-19の病理と対処法:—重症化予防セルフケアの必要性—

香月, 毅., & 佐藤, 千. (2020) · 日本健康医学会雑誌 · doi:10.20685/kenkouigaku.29.2_142

Identification of four linear B-cell epitopes on the SARS-CoV-2 spike protein able to elicit neutralizing antibodiesIdentification of four linear B-cell epitopes on the SARS-CoV-2 spike protein able to elicit neutralizing antibodiesPreprint

Li, L., Zhao, Z., Yang, X., Li, W., Chen, S., Sun, T., Wang, L., He, Y., Liu, G., Han, X., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-348597/v1

Development of a rapid SARS-CoV-2 neutralisation test by detecting antibodies that block interaction of spike protein receptor-binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2)Preprint

Richardson, C., Gildea, S., Harkin, S., Gallagher, A., Conroy, E., McClafferty, L., McCole, E., Benchikh, E. O., Reid, C. N., Dunlop, M., et al. (2021) · medRxiv · doi:10.1101/2021.06.03.21255116

SARS-CoV-2 Neutralizing Antibody has Better Diagnostic Sensitivity than IgM and IgGPreprint

Cui, S., Wang, M., Nie, J., Zhao, C., Shen, L., Wu, J., Wang, Y., Huang, W., & Chen, L. (2021) · Research Square · doi:10.21203/rs.3.rs-562694/v1

Profiles of SARS-CoV-2 RNA and Antibodies in Inpatients with COVID-19 not Related with Clinical Manifestation: A Single Centre Study

Zhao, L., Gao, R., Lu, R., Wang, H., Deng, Y. L., Niu, P., Jiang, F., Huang, B., Liang, J., Jia, J., et al. (2021) · Virologica Sinica · doi:10.1007/s12250-021-00411-w

[Widal reaction and Weil-Felix reaction].

Mizunoya, T. (1968) · PubMed

Structure and function analysis of a potent human neutralizing antibody CA521LALA against SARS-CoV-2Preprint

Dou, C., Qin, C., Wang, L., Song, D., Deng, Y., Wang, W., Dong, C., Ning, Z., Liu, X., Liu, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-141793/v1

A Safe Pseudotyped Lentivirus-Based Assay to Titer SARS-CoV-2 Neutralizing AntibodiesPreprint

Cruz-Cárdenas, J. A., Gutierrez-Mayret, M., López-Arredondo, A., Castañeda‐Delgado, J. E., Rojas‐Martínez, A., García‐Rivas, G., Enciso‐Moreno, J. A., Palomares, L. A., & Brunck, M. E. G. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4052012

Features of the humoral response to immunization "Gam-COVID-Vac" and in patients with COVID-19

Akinshina, Y. A., Mardanly, S. G., Ротанов, С. В., Pomazanov, V. V., Kiseleva, V. A., & Ermolaev, I. I. (2022) · Russian Clinical Laboratory Diagnostics · doi:10.51620/0869-2084-2022-67-4-227-233

Dispositivos elétrico-eletroquímicos verticais de grafeno: a nova geração de biossensores on chip

Mattioli, I. A. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.75.2022.tde-11052022-093819

A Visual Immunochromatographic Assay for Rapid Detection of SARS-CoV-2 Neutralizing AntibodyPreprint

Tang, Y., Zhang, Y., Chen, Y., Li, Y., He, Y., He, J., Zhang, X., Gao, Z., & Xu, J. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4145495

Current Status of Vaccines Developed for SARS-CoV-2 Infection: A Review

Hoyos, C. A. M., Sánchez, J. P. C., Gómez, R. F., & Vivas, M. C. (2022) · Bangladesh Journal of Infectious Diseases · doi:10.3329/bjid.v9i9.62614 · Cited by 1

CONVALESCENT PLASMA: ITS EFFECTIVENESS IN TREATING MODERATE AND SEVERE CASES OF COVID 19 IN A TERTIARY CARE CENTRE IN UTTARAKHAND

Batra, N., Umar, S., Uniyal, N., Kumar, A., Hatwal, D., Ojha, S., & Petwal, S. (2022) · INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · doi:10.36106/ijsr/6306670

Evaluation the correlation between anti-spike protein IgG antibody titers against SARS-CoV-2 Prototype and different Omicron variants by ELISA and neutralization activityPreprint

Yu, X., Liu, Y., Ding, Q., Qi, X., Wei, H., Zhang, Y., Li, P., Liu, J., Liu, Y., Lv, J., et al. (2023) · doi:10.22541/au.167723109.92345397/v1

Developing a pseudo-lentivirus-based neutralization assay against SARS-CoV-2Preprint

Soltani, E., Pouriayevali, M. H., Salehi-Vaziri, ‪., & Bahonar, A. R. (2023) · Research Square · doi:10.21203/rs.3.rs-2678387/v1

Author response: Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China

Zhang, H., Hua, Q., Xu, N., Zhang, X., Chen, B., Xi-jun, M., Hu, J., Chen, Z., Yu, P., Lei, H., et al. (2023) · eLife · doi:10.7554/elife.84056.sa2

Soğuk iklim bölgelerinde LEED sertifikalı eğitim binasının pandemi bağlamında değerlendirilmesi

Celik, A. (2023) · Gümüşhane Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.17714/gumusfenbil.1232091

Identification of SARS-CoV-2 Neutralizing Potency of Human Convalescent Plasma Using Pseudovirus Neutralization AssayPreprint

Tok, Y., Torabfam, G. Ç., Çimen, A. N., Güney-Esken, G., Yücebağ, E., Arslan, N., Sarıbal, D., Doğan, Ö., Kuşkucu, M. A., Mete, B., et al. (2023) · doi:10.22541/au.168903906.67219803/v1

Development of surrogate SARS-Cov-2 virus neutralization test method using plant-produced recombinant proteins

Jirarojwattana, P., & Phoolcharoen, W. (2022) · Chula Digiverse · doi:10.58837/chula.the.2022.293

การศกษาระดบแอนตบอดลบลางฤทธในผปวยโควด-๑๙ ทยนยนการตดเชอดวยปฏกรยาลกโซพอลเมอเรส แยกตามความรนแรงของโรค

ศิระวัฒนชัย, ฐ., & พุทธเจริญ, โ. (2021) · doi:10.58837/chula.the.2021.1137

A serological and molecular survey of SARS-CoV-2 infection in domestic dogs and cats in Bangkok and vicinity Thailand

Udom, K. (2021) · doi:10.58837/chula.the.2021.405

An exploratory study of drug concentration and inhibitory effect of cetylpyridinium chloride buccal tablets on SARS‐CoV‐2 infection among 10 Chinese subjects

Li, Y., Xie, Z., Chen, L., Liu, X., Li, S., Ye, S., Tang, H., Lee, C., Gu, Q., Men, F., et al. (2023) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12972

Hyperglycemia-induced cathepsin L maturation: Implications for diabetic comorbidities and COVID-19 susceptibilityPreprint

He, Q., Zhao, M., Li, M.-J., Li, X., Jin, J., Feng, Y., Zhang, L., Huang, W., Yang, F., & Yang, J. (2024) · eLife · doi:10.7554/elife.92826.1

Preliminary Application of a Coronavirus Pseudovirus System

Tao, X., Li, T., He, B., Zhao, W., Hu, S., Ma, Z., Sun, L., Li, R., Luo, L., & Li, Y. (2023) · Future Virology · doi:10.2217/fvl-2023-0131

ONE HEALTH APPROACH ON SARS-COV-2 – USING SHEEP AS SENTINEL ANIMALS TO INCREASE FUTURE PANDEMIC PREPAREDNESS – a pilot studyPreprint

Samojlović, M., Mesquita, J., Santos-Silva, S., Neptin, M., & Esbjörnsson, J. (2024) · bioRxiv · doi:10.1101/2024.03.15.585163

Proteomics Platform Reveals Broad-Spectrum Nanobodies for SARS-CoV-2 Variant Neutralization

Zhang, R., Huang, L. J., Zhang, X., Yu, Y., Liang, T., Wang, H., Zhang, X., Hu, D., Wang, B., Wang, Y., et al. (2024) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00569

The Protective Efficacy of a SARS-CoV-2 Vaccine Candidate B.1.351V against Several Variant Challenges in K18-hACE2 Mice

Yang, J. E., Fan, H., Yang, A., Wang, W., Wan, X. H., Lin, F., Yang, D., Wu, J., Wang, K., Li, W., et al. (2024) · Vaccines · doi:10.3390/vaccines12070742

Performance evaluation of four kits for the detection of neutralizing antibody against SARS-CoV-2 in human serum

Zhen, H., Cheng, Y., Sun, Q., Zheng, Y., Tian, L., Shen, C., Li, L., Gong, J., Chen, Y., & Ba, H. (2024) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2024.100192

Detection of Neutralizing Antibodies in Serum Samples Using a SARS‐CoV‐2 Pseudotyped Virus Assay

Ferrero, S., Batto, M. V., Gatto, M. I., Dimase, F., & Helguera, G. F. (2024) · Current Protocols · doi:10.1002/cpz1.70025

Influencing factors of antibody response after 2 doses of inactivated COVID-19 vaccine among adults aged ≥18 years in Chongqing, China: A cross-sectional serological study

Wang, Q., Xu, J., Liu, Y., & Li, J. (2024) · Medicine · doi:10.1097/md.0000000000040075

Evaluating the Quality of Studies Assessing COVID-19 Vaccine Neutralizing Antibody Immunogenicity

Katzmarzyk, M., Naughton, R., Sitaras, I., Jacobsen, H., Higdon, M. M., & Knoll, M. D. (2024) · Vaccines · doi:10.3390/vaccines12111238

HIV-1-Based SARS-CoV-2 Pseudotyped Virus to Determine Neutralizing Antibody Titers in Chile

Gaete-Argel, A., Acevedo, M. L., Henríquez, D. R., Soto‐Rifo, R., & Valiente‐Echeverría, F. (2024) · The Latin American studies book series · doi:10.1007/978-3-031-68419-7_10

Omicron JN.1 escape neutralization by omicron subvariants infection in elderly individuals

Liu, F., Yu, Y., Tong, J., Wu, J., Lu, Q., Liu, R., Cao, L., Ma, X., Zhu, J., Wang, T., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126658

Study of the immunogenicity, efficacy and safety of recombinant RBD SARS-CoV-2 vaccine with CpG adjuvant in rodent, non-rodent and Maccaca fascicularis using Indonesian Strain VirusPreprint

Limeilati, N. A., Nidom, R. V., Sari, T. T., Kusumarahayu, N. P., Fransiska, S. V., Indrasari, S., Garmana, A. N., Ayuningtyas, D. K., Nugroho, G. S., Darsono, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.18.629000

T‐Cell‐Dependent Bispecific IgGs Protect Aged Mice From Lethal SARS‐CoV‐2 Infection

Fu, W., Zhang, W., You, Z., Li, G., Wang, C., Lei, C., Zhao, J., Hou, J. L., & Hu, S. (2025) · Advanced Science · doi:10.1002/advs.202406980

Establishment of a pseudovirus neutralization assay for TGEV

Wang, H., Chen, J., Xue, L., Sun, Y., An, T., Wang, Y., Chen, H., Yu, C., Xia, C., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1558604

Prediction of novel high-risk variants through co-occurrence analysis of mutation hotspots

Hwang, S., Kim, K.-M., Kim, S., Park, T., Yoo, H. M., & Park, D. (2025) · Heliyon · doi:10.1016/j.heliyon.2025.e43563

Evaluating the Comparative Effectiveness of Functional Antibody Responses of Different Sars-Cov-2 Vaccination Platforms in Covid-19 Patients from Metro Manila, PhilippinesPreprint

Domingo, J. R. C., Ocampo, A. M. M., Tan‐Lim, C. S. C., Dans, L. F., Dator, M. A., Alejandro, M. A. J. I., Paz, E., Gonzales, M. L. A., & Bagamasbad, P. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5367706

Durability of neutralizing antibody and T-cell responses in COVID-19 patients after infection and booster vaccination

Lin, Y., Jiang, X., Cao, J.-X., Guo, Q., Wu, M., Wu, S., Duan, L., Shen, Y. L., Zhan, B., Lin, J., et al. (2025) · Vaccine X · doi:10.1016/j.jvacx.2025.100718

Comparative analysis of neutralization assays performed using live SARS-CoV-2 virus and pseudovirus to assess immunogenicity of a bivalent SARS-CoV-2 protein vaccine in humans

Gao, C., Yi, J., Baidoo, A. A. H., Liu, D., Li, J., Li, D., Li, J., Zhou, Q., & Xie, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1650083

Antibody preparation and immunological analysis of RBD from the SARS-CoV-2 Omicron BF.7 variant

Wang, Q., Wang, C., Zhang, Z., Fan, S., Li, M., Liu, S., Li, M., Kang, L., Zhang, Y., Kang, L., et al. (2025) · Molecular Immunology · doi:10.1016/j.molimm.2025.09.008

Establishment of rapid saturation mutagenesis and screening methods for improving the neutralizing activity of monoclonal antibodies

Wu, X., Wang, L., He, C., Shen, Y., Wang, Y., & Huang, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1722831

Development and Application of Respiratory Pseudovirus Packaging System

Fu, J., Chen, R., Zhong, S., Jiang, H., Yang, J., Ma, X., & Lu, C. (2025) · Aerosol Science and Engineering · doi:10.1007/s41810-025-00363-8

Host genomes for the unique SARS-CoV-2 variant leaked into Antarctic soil metagenomic sequencing dataPreprint

Csabai, I., & Solymosi, N. (2022) · Research Square · doi:10.21203/rs.3.rs-1330800/v1

Additional file 1 of Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor

Liu, J., Bodnar, B. H., Meng, F., Khan, A. I., Wang, X., Saribas, S., Wang, T., Lohani, S. C., Wang, P., Wei, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16544166

Additional file 1 of Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2

Li, C., Zhou, H., Guo, L., Xie, D., He, H., Zhang, H., Liu, Y., Peng, L., Zheng, L., Lu, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20317861

Additional file 2 of Potential inhibitors for blocking the interaction of the coronavirus SARS-CoV-2 spike protein and its host cell receptor ACE2

Li, C., Zhou, H., Guo, L., Xie, D., He, H., Zhang, H., Liu, Y., Peng, L., Zheng, L., Lu, W., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20317864

First pseudovirus-based assay to measure virus-elicited neutralizing antibodies in Mexico: proof-of-concept with SARS-CoV-2Preprint

Cruz-Cardenas, J. A., Gutierrez-Mayret, M. G.-M., López-Arredondo, A., Castañeda-Delgado, J. E., Rojas-Martinez, A., Nakamura, Y., Enciso‐Moreno, J. A., Palomares-Aguilera, L., & Brunck, M. E. G. (2022) · Research Square · doi:10.21203/rs.3.rs-1762570/v1

Additional file 1 of Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants

Wang, X.-J., Yao, L., Zhang, H.-Y., Zhu, K.-L., Zhao, J., Zhan, B.-D., Li, Y.-K., He, X.-J., Huang, C., Wang, Z.-Y., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22612648

Additional file 2 of Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor

Liu, J., Bodnar, B. H., Meng, F., Khan, A. I., Wang, X., Saribas, S., Wang, T., Lohani, S. C., Wang, P., Wei, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16544169

Immunological Assay-Based COVID-19 Detection

Shah, B. M., & Modi, P. (2025) · Medical virology · doi:10.1007/978-981-95-1426-7_7

Structural mimics of SARS-CoV-2

Killassy, N., Arbuthnot, P. B., & Maepa, M. B. (2026) · Infection · doi:10.1007/s15010-025-02682-x

Development of baculovirus-derived bovine parvovirus VP2based chimeric virus-like particles co-displaying SAT2 FMDV VP1 B- and T-cell epitopes and evaluation of humoral and cellular immune responses in BALB/c mice

Wubshet, A. K., Ding, Y., Zhou, L., Wang, Y., Dai, J., Li, Q., Li, G., Solomon, N., He, J., Yin, X., et al. (2026) · Virology · doi:10.1016/j.virol.2026.110812

Applications of Pseudoviruses Bearing Glycoproteins of SARS-CoV-2 and Influenza Virus

Ota, M., Sano, K., Yoshihara, K., Watanabe, S., Hasegawa, H., & Miyakawa, K. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-04153-1_22

Development and Qualification of a Pseudotyped Virus‐Based Microneutralisation Assay for Influenza D Virus

Marotta, M., Mapulanga, T., Maina, M., Daly, J., Camero, M., van Diemen, P. M., Everett, H., Montomoli, E., da Costa, K., Temperton, N. J., et al. (2026) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.70245

Poria cocos Polysaccharide Fraction PCP-II Enhances Humoral and Cellular Responses to a SARS-CoV-2 RBD Subunit Vaccine in Mice

Zhou, M., Liu, J., Zhang, X., Yan, F., Wu, Y., Huang, C., Xie, D., & Liu, B. (2026) · Vaccines · doi:10.3390/vaccines14050389

Measuring Humoral Immune Responses to SARS-CoV-2: A Comprehensive Review of Serological Assays

Xue, H., Haynesworth, K., Hempel, H., Kemp, T. J., & Pinto, L. A. (2026) · Vaccines · doi:10.3390/vaccines14050395

From COVID-19 experience to future readiness: a systematic review of pseudovirus and replicon systems in antiviral innovation

Khan, N., Lani, R., & Hassandarvish, P. (2026) · Future Virology · doi:10.1080/17460794.2026.2713361

A novel Fc-optimized anti-Ebola neutralizing antibody with extended in vivo half-life

Peng, S., Yi, Z., Hu, W., Peng, F., Zhou, X., Feng, J., Wang, N., Wen, Y., Chen, G., & Qiao, C. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108798

Validation of SARS-CoV-2 neutralization assay using VSV-based pseudovirus system

Artarini, A., Tan, M. I., Giri-Rachman, E. A., Natalia, D., Chen, D. V., Ono, C., & Matsuura, Y. (2026) · Analytical Biochemistry · doi:10.1016/j.ab.2026.116239

Human organoids and organ-on-chip systems for AI-guided therapeutic discovery against emerging and re-emerging infections

Makkar, S. K., Bhatia, S., Nguyen, N., & Wei, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1927806

Functional Evaluation of Neutralizing Antibodies Against Foot-and-Mouth Disease Virus Serotype O Using a Luciferase-Based Surrogate Neutralization Assay

Kim, H. J., Kim, D.-W., Chae, Y., Kim, Y., Cho, G., Hwang, J.-H., Lee, Y.-H., Park, J.-H., & Park, S.-H. (2026) · Viruses · doi:10.3390/v18091015

SARS-CoV-2 spike-armed vesicular stomatitis virus recapitulates severe COVID-19 acute respiratory distress syndrome in mice

Karunamurthy, P., Tieu, A., Chwastek, D., Fisk, Z. A., Chander, N., Jahandideh, F., Engelberts, D., Jamieson, T. R., Petryk, J., He, X., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117378

Mass-standardised quantitative biophotonic assay for profiling the SARS-CoV-2 spike IgG response in recovery and vaccination cohorts

James‐Pemberton, P. H., Helliwell, M. W., Olkhov, R. V., Kohli, S., Westlake, A. C., Farrar, B. M., & Shaw, A. M. (2026) · The Analyst · doi:10.1039/d6an00659k

A Versatile Single-Round SARS-CoV-2 System for Interrogating Antivirals and Host Determinants

Jiang, S. (2026) · doi:10.56902/etdcrp.2026.160

An atlas of sarbecovirus infectivity across diverse ACE2 orthologs

Sun, Y., Cheng, Z., Wu, X., Liu, K., Wang, L., Yang, D., Huang, W., & Nie, J. (2026) · iScience · doi:10.1016/j.isci.2026.117769

BindingDB Entry 50017709: Clofazimine derivatives as potent broad-spectrum antiviral agents with dual-target mechanism.

BindingDB (2023) · UC San Diego · doi:10.7270/q2sj1qqr

BindingDB Entry 50016480: Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.

BindingDB (2023) · UC San Diego · doi:10.7270/q28s4txk

Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

Nie, J., Li, Q., Wu, J., Zhao, C., Hao, H., Liu, H., Zhang, L., Nie, L., Qin, H., Wang, M., et al. (2020) · Nature Protocols · doi:10.1038/s41596-020-0394-5 · Cited by 427

Detection of Neutralizing Antibodies in Serum Samples Using a SARS‐CoV‐2 Pseudotyped Virus Assay

Ferrero, S., Batto, M. V., Gatto, M. I., Dimase, F., & Helguera, G. F. (2024) · Current Protocols · doi:10.1002/cpz1.70025

Evaluation of a Pseudovirus Neutralization Assay for SARS-CoV-2 and Correlation with Live Virus-Based Micro Neutralization Assay

Tolah, A. M., Sohrab, S. S., Tolah, K. M., Hassan, A. M., El-Kafrawy, S. A., & Azhar, E. I. (2021) · Diagnostics · doi:10.3390/diagnostics11060994 · Cited by 34

Design and Development of a Pseudotyped-lentivirus for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hassannia, H., Enderami, S. E., Mansour, R. N., Eftekhary, M., Abazari, M., & Salarinia, R. (2023) · DOAJ (DOAJ: Directory of Open Access Journals)

Pseudovirus-Based Assays for the Measurement of Antibody-Mediated Neutralization of SARS-CoV-2

Balinsky, C. A., Jani, V., Sun, P., Williams, M., Defang, G. N., & Porter, K. R. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2111-0_21 · Cited by 5